Study Summary
This trial will evaluate the long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy.
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: 15 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Participants receiving GSK adoptive cell therapy
1 of 1
Experimental Treatment
250 Total Participants · 1 Treatment Group
Primary Treatment: GSK adoptive cell therapy · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has GSK's adoptive cell therapy attained regulatory clearance?
"This early-stage trial has minimal safety or efficacy data available, so GSK's adoptive cell therapy was assigned a score of 1." - Anonymous Online Contributor
Is this research endeavor open to new participants?
"Data hosted on clinicaltrials.gov shows that this medical trial is now welcoming participants. This experiment was first put online on April 9th 2018, and has been modified as recently as November 21st 2022." - Anonymous Online Contributor
What is the current cohort size of this experiment?
"Affirmative. Clinicaltrials.gov's records show that this clinical trial, initially posted on 4/9/2018, is actively enrolling subjects with up to 250 participants being admitted at 31 different sites." - Anonymous Online Contributor
How extensively is this trial being conducted throughout the medical field?
"This clinical trial is being conducted across 31 medical centres, including New Haven, Philadelphia and Salt Lake City. To reduce any potential travel burden on participants it's recommended to choose the centre nearest you." - Anonymous Online Contributor